Intracerebral metastases natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
| Line 22: | Line 22: | ||
*The primary tumor-specific prognosis of intracerebral metastases are tabulated below:<ref name="Khuntia2015">{{cite journal|last1=Khuntia|first1=Deepak|title=Contemporary Review of the Management of Brain Metastasis with Radiation|journal=Advances in Neuroscience|volume=2015|year=2015|pages=1–13|issn=2356-6787|doi=10.1155/2015/372856}}</ref> | *The primary tumor-specific prognosis of intracerebral metastases are tabulated below:<ref name="Khuntia2015">{{cite journal|last1=Khuntia|first1=Deepak|title=Contemporary Review of the Management of Brain Metastasis with Radiation|journal=Advances in Neuroscience|volume=2015|year=2015|pages=1–13|issn=2356-6787|doi=10.1155/2015/372856}}</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: | {| style="border: 0px; font-size: 90%; margin: 3px; width:1000px" | ||
|valign=top| | |valign=top| | ||
|+ | |+ | ||
| Line 30: | Line 30: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Non-small-cell lung cancer | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Non-small-cell lung cancer | ||
| style="padding: 5px 5px; background: #F5F5F5;" |7 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|7 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |6.53 - 7.50 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|6.53 - 7.50 | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Small cell lung cancer | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Small cell lung cancer | ||
| style="padding: 5px 5px; background: #F5F5F5;" |4.9 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|4.9 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |4.30 - 6.20 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|4.30 - 6.20 | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Melanoma | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Melanoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |6.74 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|6.74 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |5.90 - 7.57 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|5.90 - 7.57 | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Renal cell carcinoma | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Renal cell carcinoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |9.63 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|9.63 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |7.66 - 10.91 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|7.66 - 10.91 | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Breast cancer | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Breast cancer | ||
| style="padding: 5px 5px; background: #F5F5F5;" |11.93 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|11.93 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |9.69 - 12.85 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|9.69 - 12.85 | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Gastrointestinal cancer | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Gastrointestinal cancer | ||
| style="padding: 5px 5px; background: #F5F5F5;" |5.36 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|5.36 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |4.30 - 6.30 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|4.30 - 6.30 | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Unknown | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |Unknown | ||
| style="padding: 5px 5px; background: #F5F5F5;" |6.37 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|6.37 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |5.22 - 7.49 | | style="padding: 5px 5px; background: #F5F5F5;" align=center|5.22 - 7.49 | ||
|} | |} | ||
Revision as of 16:17, 16 November 2015
|
Intracerebral metastases Microchapters |
|
Differentiating Intracerebral Metastases from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Intracerebral metastases natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Intracerebral metastases natural history, complications and prognosis |
|
FDA on Intracerebral metastases natural history, complications and prognosis |
|
CDC on Intracerebral metastases natural history, complications and prognosis |
|
Intracerebral metastases natural history, complications and prognosis in the news |
|
Blogs on Intracerebral metastases natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Natural History
Complications
Common complications of intracerebral metastases include:[1]
Prognosis
- Depending on the type of primary cancer, the age of the patient, the absence or presence of extracranial metastases, and the number of metastatic sites in the brain at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor.[2][3]
- The median survival time of all patients with intracerebral metastases is 2.3 months.
- The primary tumor-specific prognosis of intracerebral metastases are tabulated below:[3]
| Primary | Median survival (months) | 95% CI |
|---|---|---|
| Non-small-cell lung cancer | 7 | 6.53 - 7.50 |
| Small cell lung cancer | 4.9 | 4.30 - 6.20 |
| Melanoma | 6.74 | 5.90 - 7.57 |
| Renal cell carcinoma | 9.63 | 7.66 - 10.91 |
| Breast cancer | 11.93 | 9.69 - 12.85 |
| Gastrointestinal cancer | 5.36 | 4.30 - 6.30 |
| Unknown | 6.37 | 5.22 - 7.49 |
- However, in some patients such as those with , the prognosis is much better with the median survival rate of up to 13.5 months.
- Favorable prognostic factors (median survival rate of 13.5 months) for intracerebral metastases include:
- No extracranial metastases
- Age less than 65 years
- Single site of metastasis in the brain
References
- ↑ Andrew B. Lassman & Lisa M. DeAngelis (2003). "Brain metastases". Neurologic clinics. 21 (1): 1–23. PMID 12690643. Unknown parameter
|month=ignored (help) - ↑ Prognosis of brain metastasis. Wikipedia 2015. https://en.wikipedia.org/wiki/Brain_metastasis. Accessed on November 9, 2015
- ↑ 3.0 3.1 Khuntia, Deepak (2015). "Contemporary Review of the Management of Brain Metastasis with Radiation". Advances in Neuroscience. 2015: 1–13. doi:10.1155/2015/372856. ISSN 2356-6787.